A nonsteroidal intestinal-restricted FXR ligand known as Fexaramine has shown to ameliorate liver injury and hepatic steatosis in mice on an HFD and shows potential for the treatment of CMD [133,134]. Here, NR1H4 is linked to fatty liver disease.